Cited by 496Immunotherapy and Immune ResponsesExtracellular vesicles in diseaseT-cell and B-cell Immunology

Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells

André, Fabrice, Chaput, Nathalie, Schartz, Nöel E C, Flament, Caroline, Aubert, Nathalie, Bernard, Jacky, Lemonnier, François, Raposo, Graça +6 more·2004·The Journal of Immunology

Abstract

Current immunization protocols in cancer patients involve CTL-defined tumor peptides. Mature dendritic cells (DC) are the most potent APCs for the priming of naive CD8+ T cells, eventually leading to tumor eradication. Because DC can secrete MHC class I-bearing exosomes, we addressed whether exosomes pulsed with synthetic peptides could subserve the DC function consisting in MHC class I-restricted, peptide-specific CTL priming in vitro and in vivo. The priming of CTL restricted by HLA-A2 molecules and specific for melanoma peptides was performed: 1) using in vitro stimulations of total blood lymphocytes with autologous DC pulsed with GMP-manufactured autologous exosomes in a series of normal volunteers; 2) in HLA-A2 transgenic mice (HHD2) using exosomes harboring functional HLA-A2/Mart1 peptide complexes. In this study, we show that: 1) DC release abundant MHC class I/peptide complexes transferred within exosomes to other naive DC for efficient CD8+ T cell priming in vitro; 2) exosomes require nature’s adjuvants (mature DC) to efficiently promote the differentiation of melanoma-specific effector T lymphocytes producing IFN-γ (Tc1) effector lymphocytes in HLA-A2 transgenic mice (HHD2). These data imply that exosomes might be a transfer mechanism of functional MHC class I/peptide complexes to DC for efficient CTL activation in vivo.

Integrity signals

Registry

Crossref · 10.4049/jimmunol.172.4.2126

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
André, F., Chaput, N., Schartz, N. E. C., Flament, C., Aubert, N., Bernard, J., Lemonnier, F., Raposo, G., Escudier, B., Hsu, D.-H., Tursz, T., Amigorena, S., Angevin, E., & Zitvogel, L.
Affiliations
  • Unité d’Immunologie, ERM0208 Institut National de la Santé et de la Recherche Médicale, Department of Clinical Biology, Institut Gustave Roussy , Villejuif ,
  • Inserm (FR)
  • Institut Jean Godinot (FR)
  • Unité d’Immunologie Cellulaire Antivirale, Institut Pasteur , Paris ,
  • Unité Mixte de Recherche 144 Centre National de la Recherche Scientifique Institut Curie , Paris ,
  • Anosys, Inc. , Menlo Park, CA 94025
  • Institut National de la Santé et de la Recherche Médicale Unité 520, Institut Curie , Paris ,
Corresponding author
  • Chaput, Nathalie
  • Flament, Caroline
  • Escudier, Bernard
  • Tursz, Thomas
  • Angevin, Eric
  • Zitvogel, Laurence
Venue
The Journal of Immunology
Published
2004-02
Volume
172
Issue
4
Pages
2126-2136
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W1804501722
Cited by
496
References
3
Citations by year
2026: 11 · 2025: 22 · 2024: 31 · 2023: 20 · 2022: 41 · 2021: 33 · 2020: 32 · 2019: 24 · 2018: 24 · 2017: 23 · 2016: 21 · 2015: 22 · 2014: 19 · 2013: 17 · 2012: 22
FWCI
7.79
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
exosomes, dendritic cells, peptide-MHC complex, cell-free vaccine, CTL priming, HLA-A2, Melan-A, CD8+ T cells, T cell activation, exosome transfer, interferon-gamma, cancer immunotherapy
MeSH terms
Animals, Antigens, Neoplasm, Cell Differentiation, Cell-Free System, Cells, Cultured, Cytotoxicity, Immunologic, Dendritic Cells, Humans, Interphase, Lymphocyte Activation, Mice, Transgenic, Neoplasm Proteins, Endosomes, T-Lymphocytes, Cytotoxic, Histocompatibility Antigens Class I, HLA-A2 Antigen, Antigen Presentation, CD8-Positive T-Lymphocytes, Epitopes, T-Lymphocyte, Cancer Vaccines, Vaccines, Subunit, Cell Line, Tumor, Mice, MART-1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review